F

Amicus Therapeutics
D

FOLD

9.77000
USD
-0.04
(-0.41%)
Market Open
Volume
8,840
EPS
-0
Div Yield
-
P/E
-29
Market Cap
2,917,838,373
Related Instruments
    A
    ARWR
    0.220
    (1.13%)
    19.670 USD
    B
    BLUE
    -0.66000
    (-7.77%)
    7.83000 USD
    C
    CRSP
    -0.480
    (-1.18%)
    40.240 USD
    E
    EDIT
    -0.05500
    (-4.17%)
    1.26500 USD
    N
    NTLA
    -0.160
    (-1.31%)
    12.030 USD
    Q
    QURE
    -0.310
    (-1.82%)
    16.740 USD
    S
    SGMO
    0.05500
    (2.21%)
    2.54500 USD
    S
    SRPT
    0.000
    (0.00%)
    118.970 USD
    VRTX
    VRTX
    0.44
    (0.11%)
    399.84 USD
    More
News

Title: Amicus Therapeutics

Sector: Healthcare
Industry: Biotechnology
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.